These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Zanubrutinib ameliorates experimental idiopathic inflammatory myopathy-associated interstitial lung disease by BTK/NF-κB signaling pathway. Liu Z; Liu Z; Li W; Yang Z; Meng L; Zhang T; Chai D; Liu J; Liu Y; Jiao R; Ai X; Li X; Zhou H Int Immunopharmacol; 2024 Dec; 143(Pt 1):113313. PubMed ID: 39388891 [TBL] [Abstract][Full Text] [Related]
3. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1. Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973 [TBL] [Abstract][Full Text] [Related]
4. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387 [TBL] [Abstract][Full Text] [Related]
5. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity. Watanabe E; Kato K; Gono T; Chiba E; Terai C; Kotake S Rheumatology (Oxford); 2021 Jan; 60(1):322-332. PubMed ID: 32770187 [TBL] [Abstract][Full Text] [Related]
6. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Lv Q; Wang J; Xu C; Huang X; Ruan Z; Dai Y Mol Med; 2020 May; 26(1):49. PubMed ID: 32448163 [TBL] [Abstract][Full Text] [Related]
7. Proinflammatory Histidyl-Transfer RNA Synthetase-Specific CD4+ T Cells in the Blood and Lungs of Patients With Idiopathic Inflammatory Myopathies. Galindo-Feria AS; Albrecht I; Fernandes-Cerqueira C; Notarnicola A; James EA; Herrath J; Dastmalchi M; Sandalova T; Rönnblom L; Jakobsson PJ; Fathi M; Achour A; Grunewald J; Malmström V; Lundberg IE Arthritis Rheumatol; 2020 Jan; 72(1):179-191. PubMed ID: 31403245 [TBL] [Abstract][Full Text] [Related]
8. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Laporte A; Mariampillai K; Allenbach Y; Pasi N; Donciu V; Toledano D; Granger B; Benveniste O; Grenier PA; Boussouar S Eur Radiol; 2022 May; 32(5):3480-3489. PubMed ID: 35022809 [TBL] [Abstract][Full Text] [Related]
9. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. Hisatomi K; Mukae H; Sakamoto N; Ishimatsu Y; Kakugawa T; Hara S; Fujita H; Nakamichi S; Oku H; Urata Y; Kubota H; Nagata K; Kohno S BMC Pulm Med; 2012 Jun; 12():24. PubMed ID: 22694981 [TBL] [Abstract][Full Text] [Related]
11. Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway. Paik SS; Lee JM; Ko IG; Kim SR; Kang SW; An J; Kim JA; Kim D; Hwang L; Jin JJ; Kim SH; Cha JY; Choi CW Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125585 [TBL] [Abstract][Full Text] [Related]
12. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328 [TBL] [Abstract][Full Text] [Related]
13. The mitigating effect of para-hydroxycinnamic acid in bleomycin-induced pulmonary fibrosis in mice through targeting oxidative, inflammatory and fibrotic pathways. Hussein ZA; Abu-Raghif AR; Fawzi HA Basic Clin Pharmacol Toxicol; 2024 Jul; 135(1):23-42. PubMed ID: 38745367 [TBL] [Abstract][Full Text] [Related]
14. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: A retrospective and prospective study. Chen Y; Bai Z; Zhang Z; Hu Q; Zhong J; Dong L Front Immunol; 2022; 13():978429. PubMed ID: 36119045 [TBL] [Abstract][Full Text] [Related]
16. XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-β1-stimulated C3H10T1/2 cells via Smad2/4. Jin SF; Ma HL; Liu ZL; Fu ST; Zhang CP; He Y Exp Cell Res; 2015 Dec; 339(2):289-99. PubMed ID: 26589264 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). Wu C; Lin H; Zhang X Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816 [TBL] [Abstract][Full Text] [Related]
18. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Tian XL; Yao W; Guo ZJ; Gu L; Zhu YJ Chin Med Sci J; 2006 Sep; 21(3):145-51. PubMed ID: 17086734 [TBL] [Abstract][Full Text] [Related]
19. The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease. Huang HL; Lin WC; Lin PY; Weng MY; Sun YT Neurol Sci; 2021 Jul; 42(7):2855-2864. PubMed ID: 33211209 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay. Jee AS; Parker MJS; Bleasel JF; Troy LK; Lau EM; Jo HE; Teoh AKY; Webster S; Adelstein S; Corte TJ Respir Med; 2021 Oct; 187():106581. PubMed ID: 34454312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]